1. Scrip
  2. >>Archive

Park resigns from Isotechnika as ILJIN takes control

 
• By Gemma Sharman

Daniel Park has resigned his position as chief business officer of Isotechnika Pharma, a biopharmaceutical company developing immunomodulating therapeutics, to avoid potential conflicts of interest that may arise as a result of his position as executive vice-president of ILJIN Life Science, which Mr Park has informed Isotechnika, intends to "increase its level of control within the company". Mr Park will remain on Isotechnika's board of directors.

Daniel Park has resigned his position as chief business officer of Isotechnika Pharma, a biopharmaceutical company developing immunomodulating therapeutics, to avoid potential conflicts of interest that may arise as a result of his position as executive vice-president of ILJIN Life Science, which Mr Park has informed Isotechnika, intends to "increase its level of control within the company". Mr Park will remain on Isotechnika's board of directors.

In addition, Dr Robert Foster has relinquished the title of chair of Isotechnika's board to Dr Peter Wijngaard, vice-president and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By Mandy Jackson

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

 
• By Alaric DeArment

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 
• By Joseph Haas, Manas Mishra, and Sushmita Panda

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.